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Abstract
Paracoccidioidomycosis, PCM, the major systemic mycosis in Latin America, is caused by the termally dimorphic fungus
Paracoccidioides brasiliensis and requires extended periods of chemotherapy with a significant frequency of relapsing
disease. The search for new alternatives of treatment is necessary. rPb27 is an antigenic protein from P. brasiliensis that
already showed a significant protective activity as a vaccine for PCM in experimental models. The cDNA of rPb27 was
subcloned into a pET-DEST 42 plasmid, expressed in E. coli with a his-tag and purified by affinity chromatography.
Immunization with this recombinant protein and chemotherapy were used together in an attempt to improve treatment of
PCM. For this, BALB/c mice were challenged with pathogenic P. brasiliensis strain and after immunized with rPb27, in the
presence of Corynebacterium parvum and Al(OH)3, some groups were also treated with fluconazole. After 40 days of
treatment, the combined drug/rPb27 administration controlled PCM in the liver and spleen, with long lasting protection,
and largely preserved tissues structures of these organs. Additionally, in the lungs after 40 days of treatment there was a
significant reduction in the fungal load and size of lesions. At the same time, the levels of TNF-a were higher than infected-
only mice. Moreover, significant levels of anti-rPb27 specific IgG1, IgG2a and IgG2b isotypes were detected in the sera of
mice immunized with rPb27 fluconazole treated or not. These results showed an additive protective effect of rPb27
immunization and chemotherapy, suggesting that an rPb27-based vaccine can be used to enhance PCM antifungal
treatment.
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Introduction
Paracoccidioidomycosis (PCM) is a systemic granulomatous
disease caused by Paracoccidioides brasiliensis, a termally dimorphic
fungus widespread in Latin America mainly affecting rural workers
[1]. PCM is the most prevalent systemic endemic mycosis in South
America notably in Brazil, Colombia, Venezuela and Argentina
[2]. The fatal acute PCM affects the reticule endothelial system,
whereas the chronic PCM affects mainly the lung, which shows a
granulomatous inflammation with an inefficient cellular immune
response [1,3].
Antifungal chemotherapy is required to control the disease. The
conventional treatment of PCM is based on sulfonamides,
amphotericin B and azole derivates. Extended periods of therapy
are usually required to warrant a good clinical response and avoid
relapses [1]. But, the prolonged time of drugs administration causes
frequent self-exclusion of the patient from treatment [1]. The
introduction of azoles marked an advance in the treatment of fungal
diseases, PCM among them. Azoles act on ergosterol biosynthesis at
the C-14-demethylationstage,and the resultingergosteroldepletion
and accumulation of 14-methylated sterols interferes with the
functions of ergosterol as a membrane component, altering the
normal permeability and fluidity of the fungal membrane [2].
Imidazoles (ketoconazole) and triazoles (fluconazole, saperconazole,
and itraconazole) have been extensively used for the treatment of
PCM and have proven effective for clinical purposes, showing fewer
side effects than amphotericin B [1].
The above mentioned antifungal antibiotics have drawbacks
such as long time of medication (sulfa derivates and azoles), severe
renal side effects (amphotericin B), unresponsiveness of some
patients to the treatments (all antifungals) [1,4,5,6,7,8] and high
cost (azoles, lipid formulations of amphotericin B). Therefore, the
search for new and more effective strategies to conventional
chemotherapy for P. brasiliensis and other fungal pathogenic
species, with fewer or no side effects, continues [3].
Because of the search for these new alternatives for PCM
treatment, several candidate antigen molecules and its mecha-
nisms of protection against P. brasiliensis are being studied. Among
these molecules, the recombinant protein rPb27 represents an
attractive candidate due to its great potential to control this disease
as it was demonstrated in previous work [9], in which this protein
showed a significant degree of protection in the lungs, livers and
spleens of mice immunized with it and posteriorly challenged with
a virulent strain of P. brasiliensis. In this same work it was shown
PLoS ONE | www.plosone.org 1 March 2011 | Volume 6 | Issue 3 | e17885that this protein is component of F0 fraction of this fungus. This
fraction had already demonstrated protective ability in experi-
mental PCM [10].
The association of imunotherapeutics and antifungal agents to
treat PCM has also been investigated. The administration of the
peptide P10, a 15-amino acid peptide identified in the glycoprotein
Gp43, that have already shown the capacity to elicit the secretion
of Th1 type cytokines [11], as an adjuvant to the chemicals used in
the PCM therapy, showed an improvement of the therapeutic
effectiveness of some antifungal agents [11,12].
In this work we evaluated the immunotherapeutic potential of
rPb27 immunization with or without fluconazole chemotherapy to
treat PCM as well as the cytokines profile and IgG isotypes
production induced by this combined treatment in experimental
PCM using BALB/c mice.
Results
Cloning, expression and purification of recombinant
rPb27
Cloning and sequencing of rPb27 DNA resulted in 773 bp
comprising the entire rPb27 gene open reading frame and some
nucleotides that were added by the plasmid. Nucleotide sequence
homology was 100% in relation to the coding region of the 27 kDa
P. brasiliensis hypothetic protein - access number AA49615 (Data
not shown). Nucleotide sequence of this protein was cloned into a
pET-DEST42 expression vector where a recombinant protein of
approximately 27 kDa was expressed with a his-tag and then
purified by affinity cromatography. After this purification it was
possible to obtain a single protein with a good yield, as
demonstrated by SDS-PAGE and western blotting assays (Fig. 1).
Organ CFU from intratracheally infected BALB/c mice
immunized with rPb27 and/or treated with fluconazole
To explore the combined effect of rPb27 immunization and
fluconazole treatment in BALB/c mice, animals immunization
and chemotherapy started 30 days after infection. Analysis of
organ CFU was done after 40 and 90 days of treatment. A
significant reduction of fungi recovered from lung, spleen and liver
of animals (CFU) was obtained in mice immunized with rPb27
and treated with fluconazole at the first time point. In the lung of
these animals it was determined, 40 days post treatment, a 60%
reduction in the CFUs in relation to infected-only group. Besides,
in the liver and spleen of these animals there wasn’t recovered any
fungi colonie at the two time points analyzed. The rPb27
immunization alone failed to reduce fungi recovered from these
organs. And the treatment with the antifungal drug alone also
failed to reduce the number of CFU in the lung and liver at two
time points, and in the spleen after 90 days of treatment despite a
reduction after 40 days (Fig. 2 A, B).
In the lungs despite a significant reduction of fungi recovered at
the first time point analyzed in mice immunized with rPb27 and
treated with fluconazole (Fig. 2A), after 90 days of treatment this
number increased and matched the levels of infected-only group
(Fig. 2B).
Lung, spleen and liver histopathology from BALB/c mice
vaccinated with rPb27 and/or treated with fluconazole
Histopathology of lung, liver and spleen sections showed
differences in granuloma lesions. Lungs of animals only infected
with P. brasiliensis, infected and submitted to fluconazole treatment,
or infected and immunized with rPb27 (Fig. 3, 4) showed, at the
two time points investigated, giant confluent granulomes with
innumerable viable yeast cells of P. brasiliensis, and extensive tissue
destruction. While in the liver and spleen (Fig. 3, 4) of these groups
it was observed multiple foci of granulomatous inflammation,
containing fungal cells, however the group infected and treated
with fluconazole and the group immunized with rPb27 presented a
decrease on lesions size in the liver after 90 days of treatment
(Fig. 4) in relation to infected-only group. And at the first time
point analyzed (Fig. 3) the group infected and treated with
fluconazole didn’t present any considerable lesion in the liver and
spleen. The groups of mice that were innoculated with adjuvant
with or without chemotherapy presented similar pattern of lesions
than infected-only mice in the three organs analyzed (data not
shown).
Mice immunized with rPb27 and also treated with fluconazole
showed after 40 days of treatment a considerable reduction in the
size of lesions at lungs, presenting few pulmonary compact
granulomes with no confluence (Fig. 3). These granulomes were
more organized and with a reduced number of yeast cells that all
other groups analyzed (Fig. 5). The lungs of other infected groups
(Infected, Infected/T, Adjuvant, Adjuvant/T and rPb27) present-
ed a desorganized granulome with a great number of viable yeast
Figure 1. Purified rPb27 profile. A. SDS-PAGE analysis of rPb27 after
purification on HiTrap
TM Chelating HP (Amersham Biosciences, Uppsala
Sweden). Aliquot of 20 ml of purified rPb27 was separated on 10%
polyacrylamide gels, under reducing conditions, followed by Comassie-
blue staining. B. Western blotting analysis of purified rPb27 using
mouse IgG anti-his-tag (Amersham Biosciences, Uppsala Sweden).
Purified rPb27 was subjected to 10% SDS-PAGE, under reducing
conditions, followed by eletrophoretic transfer to nitrocellulose paper.
The membrane was incubated with mouse IgG anti-his-tag (1:100) and
revealed with goat anti-mouse IgG conjugated with peroxidase
(1: 10000). 1, molecular marker. 2, purified rPb27. The molecular weight
(kDa) of molecular marker proteins is showed on the left.
doi:10.1371/journal.pone.0017885.g001
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immunized with rPb27 and also treated with fluconazole presented
in lungs a pattern of granulome similar to infected group (Fig. 4,
5), and in the spleen and liver this group didn’t present any
considerable injury at the two time points analyzed (Fig. 3 and 4).
Recombinant rPb27 specific immunoglobulin responses
in infected mice
The specific antibody response to rPb27 in infected mice were
evaluated by ELISA. After three rounds of vaccination, significant
levels of anti-rPb27 IgG were detected in the sera of mice immunized
with rPb27, treated or not with fluconazole. The other groups infected
with P. brasiliensis didn’t present significant antibodie levels for this
protein, as well as the group without any intervention (data not shown).
Significant levels of anti-rPb27 specific IgG1, IgG2a and IgG2b
isotypes were detected in the sera of mice immunized with rPb27
treated or not with fluconazole compared to sera from noninfected
mice after 40 (Fig. 6A) and 90 days of treatment (Fig. 6B), while
significant levels of IgG3 were found only in the group rPb27 after 40
(Fig. 6A) and 90 days of treatment (Fig. 6B). The other groups
infected with P. brasiliensis (Infected, Infected/T, Adjuvant, Adjuvant/
T) didn’t present significant levels of these isotypes (data not shown).
Figure 2. Fungal recovery in lung, spleen and liver of infected mice. The CFUs were estimated 40 (A) and 90 days (B) post treatment in
organs from mice infected intratracheally with 3610
5 P. brasiliensis yeast cells and subjected to fluconazole treatment combined or not with rPb27
immunization. Control mice were only infected with P. brasiliensis (Infected), adjuvant mice were inoculated with C. parvum-Al(OH)3 with fluconazole
treatment (Adjuvant/T) or not (Adjuvant), and rPb27 mice were immunized with recombinant protein combined to fluconazole treatment (rPb27/T)
or not (rPb27). All groups of mice were infected with the same number of yeast cells. Bars represent the Log10(UFC/g) means and standard deviations
from organs of 3 to 5 animals in each group. * significant (p,0,05) difference in relation to the group of mice only infected.
doi:10.1371/journal.pone.0017885.g002
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Considering the increase in the worldwide incidence of fungal
infections, the development of new therapies for these diseases has
become of great importance to public health [13]. The current
therapy to treat mycosis is based on polienes and azoles,
depending on the severity of the infection [14]. To treat severe
cases of PCM amphotericin B followed by itraconazole and
sulfametoxazole are indicated. The main disadvantage of using
amphotericin B is its occasional toxicity. In the case of itraconazole
or sulfametoxazole, the long period of treatment required may
cause patients to quit medication, possibly leading to recurrence of
disease [14]. Given these dificulties, new approaches to the
treatment of systemic fungal infections need to be developed.
Alternative strategies to conventional chemotherapy for fungal
diseases have been explored. Combined therapy of immunother-
apeutics and antifungal agents in the treatment of PCM has been
investigated, and have demonstrated a great potential to enhance
antifungal effect and to prevent relapses [11,12].
Here we reported the efficacy of rPb27 immunization combined
with fluconazole chemotherapy in the treatment of PCM. rPb27 is
a recombinant protein that was firstly described by McEwen and
coworkers [15], and have demonstrated a great potential in
immunodiagnosis of PCM [16,17,18] and as a vaccine candidate
Figure 3. Representative histopathology of lungs, livers and spleens from infected mice, after 40 days of treatment. BALB/c mice
were euthanized 40 days after treatment. The lungs, spleens, and livers were excised, fixed in 10% buffered formalin, and embedded in paraffin for
sectioning. The sections were stained with hematoxylin–eosin and examined microscopically. Infected, group only infected with P. brasiliensis.
Infected/T, same as Infected, but treated with fluconazole. rPb27, group infected and posteriorly immunized with rPb27. rPb27/T, same as rPb27, but
treated with fluconazole. In each lung photos, the scale bar represents 427.3 mm, while in each liver and spleen photos, the scale bar represents
56.9 mm.
doi:10.1371/journal.pone.0017885.g003
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the immunization with this protein showed a significant degree of
protection in the lungs, livers and spleens of mice posteriorly
challenged with a virulent strain of P. brasiliensis [9]. In this work
the expression and purification of this protein showed a single
protein with approximatelly 27 kDa of molecular mass.
After 40 and 90 days of treatment the fungal load was examined
in lungs, livers and spleens of infected mice. The pattern of CFU in
these organs showed an additive effect of rPb27 immunization and
drug treatment. In lungs at the first time point analyzed this
combined treatment reduced in 60% the CFU number in relation
to control groups (untreated infected animals and those that
received adjuvant), however, this CFU number increased after 90
days of treatment reaching the Infected group levels. This
relapsing effect in lungs can be assigned to the short time of
treatment.
In the liver and spleen the combined treatment reduced in
100% the CFU number in comparison to control groups, at the
two time points analyzed. Showing that, in these organs the
combined administration of rPb27 and fluconazole controlled the
relapsing effects.
Histopathological analysis of infected mice confirmed the
therapeutic effect of rPb27 immunization combined with flucon-
azole chemotherapy, by leading to fungal elimination, reaching
Figure 4. Representative histopathology of lungs, livers and spleens from infected mice, after 90 days of treatment. BALB/c mice
were euthanized 90 days after treatment. The lungs, spleens, and livers were excised, fixed in 10% buffered formalin, and embedded in paraffin for
sectioning. The sections were stained with hematoxylin–eosin and examined microscopically. Infected, group only infected with P. brasiliensis.
Infected/T, same as Infected, but treated with fluconazole. rPb27, group infected and posteriorly immunized with rPb27. rPb27/T, same as rPb27, but
treated with fluconazole. In each lung photos, the scale bar represents 416.6 mm, while in each liver and spleen photos, the scale bar represents
55.6 mm.
doi:10.1371/journal.pone.0017885.g004
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sterility wasn’t reached by other authors using similar strategies of
therapeutic vaccines [11,12,19].
In the mice lungs rPb27 immunization with fluconazole
chemotherapy reduced CFU in this organ, at the first time point
analyzed. In addition, histopathological analyses of the group that
received this combined treatment showed less lung tissue
compromised 40 days after treatment, presenting large preserved
areas with compact, well organized granulomes containing few P.
brasiliensis yeast cells. But after 90 days of treatment the lungs of
this group showed an increase in lung tissue compromised and its
granulomes reached the extension and organization of those from
control groups, which validates the CFU assay results. Preliminary
cytokine screening showed that animals that received rPb27
immunization with fluconazole chemotherapy presented high
levels of TNF-a when compared with only-infected group after 40
days of treatment (data not shown). This result conforms with the
literature that TNF-a has a protective role in P. brasiliensis infection
and may have contributed to the reduced size of lung tissue
compromised in addition to a decrease on CFU numbers and to a
better organization of granulomes when compared to only-
infected group. TNF-a is a Th1 cytokine that according to
previous work has a great importance to control dissemination and
growth of the fungi, and inflammatory response in PCM [20].
These authors used mice with homologous disruption of the TNF-
a receptor p55 infected with P. brasiliensis and demonstrated that
these animals, but not wild-type mice, were unable to control the
growth of yeast cells and the mice succumbed to infection by day
90 after infection. Besides, inflammatory granulomas weren’t
found in these knockout animals. These findings showed that
TNF-a mediate resistance to P. brasiliensis infection [20]. In fact,
the granulomatous inflammatory reaction, a specialized and
efficient tissue response against certain parasites [21], P. brasiliensis
among them, requires TNF-a which is supposed to be responsible
for attracting and activating effector cells as well as for
macrophage accumulation and differentiation [22]. Besides this,
a recent work showed that spleen cells from infected female mice
produced more TNF-a than those from males in response to
paracoccin stimulus, which contributes to the greater resistance to
PCM presented by female in relation to male mice [23].
Summarizing, the rPb27 immunization combined to flucona-
zole chemotherapy was efficient to avoid fungal dissemination to
spleen and liver of mice and to control yeast cells growth in the
lungs after 40 days of treatment, but this control in lungs was lost
after the suspension of chemotherapy, 90 days post treatment, this
can be due to the short time of treatment, only thirty days. In the
literature it was mentioned that resistance to P. brasiliensis infection
is determined mainly by the ability of the host to restrict fungal
dissemination rather than control fungal growth at the primary site
of infection [24]. This containment of the fungus in the lungs can
be the first step to PCM control, and, possibly, with a larger time
of chemotherapy this disease could be controlled.
The specific antibody levels was also evaluated. We demon-
strated that immunization of BALB/c mice with rPb27 induced
significant levels of all isotypes evaluated after 40 and 90 days of
treatment. When this immunization was combined with flucon-
azole chemotherapy mice developed a pulmonary-restricted PCM
associated with low mortality rates and production of significant
levels of IgG1, IgG2a and IgG2b isotypes after 40 and 90 days of
treatment, with a small production of IgG3 only 40 days after
treatment. The presented data showed that the immunization with
rPb27 promoted enhanced antifungal protection by fluconazole
chemotherapy, decreasing fungal load in lungs after 40 days of
treatment and avoiding fungal dissemination to other sites of
Figure 5. Representative granulome histopathology of lungs from infected mice after 40 and 90 days of infection. BALB/c mice were
euthanized 40 and 90 days after treatment. The lungs, spleens, and livers were excised, fixed in 10% buffered formalin, and embedded in paraffin for
sectioning. The sections were stained with hematoxylin–eosin and examined microscopically. Infected, group only infected with P. brasiliensis.
Infected/T, same as Infected, but treated with fluconazole. rPb27/T, group infected and posteriorly immunized with rPb27 and treated with
fluconazole. In each photo, the scale bar represents 25.9 mm.
doi:10.1371/journal.pone.0017885.g005
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adjuvant for PCM therapy.
Materials and Methods
Ethics Statement
All animals were handled in strict accordance with good animal
practice as defined by the relevant national and local animal welfare
bodies, and all animal work was approved by the Ethics Committee
on Animal Experimentation (CETEA) from the Universidade
Federal de Minas Gerais (UFMG). The protocol number is 24/2006.
Animals used in this work
Adult male BALB/c mice (6–8 weeks old) were purchased from
Centro de Bioterismo, ICB-UFMG (Belo Horizonte, MG, Brazil),
and maintained under standard laboratory care as previously
described [10].
P. brasiliensis strain
Virulent P. brasiliensis human isolate was obtained from a patient
with active PCM, whose case was reported by Araujo and
coworkers [25], maintained in YPD agar medium [0.5% yeast
extract, 0.5% peptone, 1.5% D-glucose, 1.5% agar, pH 7.0]
(Sigma, St. Louis, MO, USA) at 36uC and collected on the seventh
day of culture. The viability of fungal suspensions determined by
staining with Janus Green B vital dye method [26] (Merck.
Darmstadt, Germany) was always higher than 90%. The virulence
of the human isolate was checked in each experiment by infecting
intratracheally BALB/c mice and recovering the yeast cells from
their organs.
Subcloning and sequencing of rPb27 DNA
The sequence of the recombinant rPb27 was already cloned by
our group in previous work into the expression vector pGEX 4T-2
(GIBCO BRL), which produces a recombinant protein fused to
glutathione S-transferase (GST) [9]. In order to facilitate the
purification procedure and avoid the contamination of purified
protein with thrombin, the rPb27 sequence was transferred to the
expression vector pET-DEST 42 (Invitrogen, Carlsbad, USA)
which express the recombinant protein with a C-terminal His-tag.
The cloning procedure was based on GatewayH technology
(Invitrogen, Carlsbad, USA), that uses an strategy based on the
recombinational properties of bacteriophage lambda [27]. The
primer set for amplification of the rPb27 sequence included the
forward primer: 59- GGGG ACA AGT TTG TAC AAA AAA
GCA GGC TTC GAA GGA GAT AGA ATG GCA CGA GCG
CTC AGT TC -39 and reverse primer: 59- GGG GAC CAC TTT
GTA CAA GAA AGC TGG GTC GTT GTG GAA GAC AGC
GCT GCA -39. The PCR annealing temperature was 56uC. The
PCR products were separated in 1% agarose gel. The blunt-end
PCR products were then cloned into pDONR 221 vector
according to the manufacturer’s protocol (Invitrogen, USA). The
reaction mixture was incubated overnight at 25uC. The reaction
was then stopped with 10 minutes Proteinase K incubation. After
this ste, competent E. coli (TOP10) was transformed by
electroporation with the pDONR 221/rPb27 construct according
to the manufacturer’s protocol (Invitrogen, USA). Positive clones
were selected on (LB) medium containing 50 mg/mL kanamycin.
Plasmid DNA was isolated using the high pure plasmid extraction
kit, Mini-prep QIAprep Spin miniprep 150 (Qiagen, Hilden,
Germany). The presence of the insert was confirmed by PCR and,
finally, to confirm the fidelity of the sequence, DNA sequencing
was performed. This construct is called the entry clone. The LR
recombination reaction was then carried out between the entry
clone and destination vector, pET-DEST42, according to the
manufacturer’s instructions (Invitrogen, USA). Competent E. coli
(BL21) were transformed by electroporation with the products of
LR recombination according to the manufacturer’s protocol.
Positive clones were analysed by culturing them on LB medium
containing 100 mg/mL ampicillin. The recombinant plasmid
pET-DEST42/rPb27 was checked for accurate insertion by
restriction enzyme analysis, and the inserted fragment was
sequenced on a MegaBACE DNA Analysis System (Amersham
Biosciences, Buckinghamshire, England) [28]. The sequence
homology with rPb27 was analyzed using the algorithm ClustalW
available on the Internet: http://www.ebi.ac.uk/clustalw/.
Expression in E. coli and purification of rPb27
The recombinant protein, rPb27, was expressed in E. coli using
the expression vector pET-DEST42 (Invitrogen, USA), which
produces a recombinant protein with a C-terminal his-tag.
Purification of the recombinant protein was therefore undertaken
Figure 6. IgG isotypes production against rPb27 by infected
and immunized mice. Antibody response against rPb27 in mice
infected and immunized with this recombinant protein associated or
not with fluconazole chemotherapy was determined by ELISA assay
after 40 (A) and 90 (B) days of treatment. Control, mice without any
intervention. rPb27, group infected and posteriorly immunized with
rPb27. rPb27/T, same as rPb27, but treated with fluconazole. Bars
represent the means and standard deviations of optical density (O.D.) at
1:400 serum dilution in each experimental group (n=3). * significant
(p,0,05) difference in relation to the control group. # significant
(p,0,05) difference in relation to the rPb27 group.
doi:10.1371/journal.pone.0017885.g006
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TM Chelating HP according to the manufacturer’s
instructions (Amersham Biosciences, Uppsala Sweden).
Sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) and Western blotting
Purified rPb27 was subjected to continuous electrophoresis
using SDS 10% polyacrylamide gels under reducing conditions
[29]. The separated proteins were stained with Coomassie blue or
transferred to a nitrocellulose membrane [30], blocked with 1.6%
of casein in phosphatebuffered saline (PBS), pH 7.4, for 1 h at
room temperature and then incubated with mouse IgG anti-his-
tag (Amersham Biosciences, Uppsala Sweden) diluted 1:100 in
0.25% casein-PBS for 1 h at room temperature. After this step the
membranes were incubated with specific secondary antibody
peroxidase-conjugated diluted 1:10000 in 0.25% casein-PBS for
1 h at room temperature and developed with diaminobenzidine
(0.6 mg/ml) in PBS, pH 7.4, plus H2O2 (1 ml/ml) and NiCl2
(10 ml/ml). The reaction was stopped with deionized water.
Intratracheal infection of BALB/c mice
Male BALB/c mice were inoculated intratracheally with 3610
5
viable yeast cells of virulent P. brasiliensis, grown on YPD-agar and
suspended in sterile PBS. Briefly, mice were anesthetized i.m. with
40 ml of a solution containing 57% of ketamine (Dopalen,
Vetbrands, Brazil) and 43% of xylazine (Dopaser, Laborato ´rio
Calier do Brasil LTDA, Brazil); after approximately 10 min, their
neckswere hyper-extended,andthe tracheawasexposedatthelevel
of the thyroid and injected with 3610
5 yeast cells in 50 mlo fP B S
using a 30-gauge needle. The incisions were sutured with 4-0 silk.
Immunization of mice with rPb27
After 30 days of infection, groups of male BALB/c mice were
immunized by subcutaneous injection of 50 mg rPb27 in the
presence of 100 mg Corynebacterium parvum and 1 mg aluminum
hydroxide, Al(OH)3, as an adjuvant. Animals were boosted three
times, at two week intervals, with the same amount of antigen.
Control mice were inoculated with adjuvant.
Chemotherapy of infected mice
After 30 days of infection animals were treated for 30 days
during which groups of mice received doses every 24 h of
fluconazole 10 mg/Kg (Mantena laboratories limited). All drug
administration were intraperitoneal.
Groups of mice studied
Male BALB/c mice were divided in seven groups of 12 animals
each: Immunized with rPb27 treated with fluconazole (rPb27/T)
or not (rPb27); injected with C. parvum-Al(OH)3 as an adjuvant
fluconazole treated (Adjuvant/T) or not (Adjuvant); infected only
(Infected); infected and treated with fluconazole (Infected/T); and
a control group without any intervention (Control).
Fungal recovery in organs of infected mice
Organ colony-forming units (CFUs) were evaluated after 40 and
90 days of treatment in the lungs, spleens and livers, which were
removed, weighed and homogenized in PBS. The final suspension
was placed on brain heart infusion (BHI, Difco) agar supplement-
ed with 4% fetal calf serum and 5% spent culture medium of
P. brasiliensis as a growth factor. Gentamycin was added at 40 mg/
l. The plates were incubated at 36uC and read after 20 days. The
results were expressed as the number of log10 of viable P. brasiliensis
CFUs per gram of tissue per mouse.
Enzyme-linked immunosorbent assay (ELISA)
ELISA plates were coated overnight at 4uC with 1 mg/100 mlo f
purified rPb27 recombinant protein in 0.05 M carbonate/
bicarbonate buffer, pH 9.6. Wells were blocked for 1 h at 37uC
with 1.6% casein in PBS solution. Plates were then incubated with
100 ml of anti-rPb27 mouse serum or non-immunized mouse
serum samples diluted 1:400 in 0.25% casein in PBS for 1 h at
37uC. Washes were performed with PBS-T20 (0.15 M PBS,
pH 7.4; 0.1% Tween-20) between incubations. For each well,
100 ml of peroxidase-conjugated goat anti-mouse IgG, IgG1,
IgG2a, IgG2b or IgG3 antibodies (Southern Biotechnology
Associates, Inc., Birmingham, AL, USA) diluted 1:5000 were
added and incubated for 1 h at 37uC. After additional washes,
peroxidase activity was assayed with 100 ml of TMB ELISA
substrates solution (Thermo Scientific Pierce). Color development
was stopped with 50 mlo f2 NH 2SO4. The optical density at
450 nm was measured with an automated ELISA reader (ELX
800 BIO-TEK Instruments Inc.).
Histopathology of lung, spleen, and liver of experimental
groups
BALB/c mice were euthanized 40 and 90 days after treatment.
The lungs, spleens, and livers were excised, fixed in 10% buffered
formalin, and embedded in paraffin for sectioning. The sections
were stained with hematoxylin–eosin and examined microscopi-
cally [9].
Statistical analysis
Data were analyzed statistically by one-way ANOVA followed
by the Bonferroni test or Student t-test associated when necessary
to the non-parametric Mann–Whitney test, with the level of
significance set at p,0.05.
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